| Autor: |
Geiger K; Johns Hopkins University School of Nursing, Baltimore, MD, USA., Patil A; Johns Hopkins Center for Infectious Disease and Nursing Innovation, Baltimore, MD, USA., Bergman A; Johns Hopkins University School of Nursing, Baltimore, MD, USA., Budhathoki C; Johns Hopkins University School of Nursing, Baltimore, MD, USA., Heidari O; Johns Hopkins Center for Infectious Disease and Nursing Innovation, Baltimore, MD, USA., Lowensen K; Johns Hopkins Center for Infectious Disease and Nursing Innovation, Baltimore, MD, USA., Mthimkhulu N, McNabb KC; Johns Hopkins University School of Nursing, Baltimore, MD, USA., Mmed NN; National Department of Health, TB Control and Management, Pretoria, South Africa., Ngozo J; KwaZulu Natal Department of Health, Pietermaritzburg, South Africa., Reynolds N; Johns Hopkins University School of Nursing, Baltimore, MD, USA., Farley JE; Johns Hopkins University School of Nursing, Baltimore, MD, USA. |
| Abstrakt: |
BACKGROUND: Understanding relationships between HIV and multidrug-resistant TB (MDR-TB) is crucial for ensuring successful MDR-TB outcomes. METHODS: We used a cross-sectional analysis to evaluate sociodemographic and clinical characteristics as correlates of antiretroviral therapy (ART) use, having an HIV viral load (VL) result, and HIV viral suppression in a cross-sectional sample of people with HIV (PWH) and MDR-TB enrolled in a cluster-randomized trial of nurse case management to improve MDR-TB outcomes. RESULTS: Among 1,479 PWH, the mean age was 37.1 years; 809 (54.7%) were male, and 881 (59.6%) were taking ART. Housing location, employment status, and CD4 count differed significantly between those taking vs. those not taking ART. Among the 881 taking ART, 681 (77.3%) had available HIV VL results. Housing location, CD4 count, and prior history of TB differed significantly between those with and without a VL result. Among the 681 with a VL result, 418 (61.4%) were virally suppressed. Age, education level, CD4 count, TB history, housing location, and ART type differed significantly between those with and without viral suppression. CONCLUSION: PWH presenting for MDR-TB treatment with a history of TB, taking a protease inhibitor, or living in a township may risk poor MDR-TB outcomes. |
